Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Accumulated Expenses (2017 - 2025)

Serina Therapeutics (SER) has disclosed Accumulated Expenses for 9 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 15.54% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, down 15.54% year-over-year, with the annual reading at $1.2 million for FY2025, 15.54% down from the prior year.
  • Accumulated Expenses hit $1.2 million in Q4 2025 for Serina Therapeutics, up from $1.1 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.4 million in Q4 2024 to a low of $111000.0 in Q1 2024.
  • Historically, Accumulated Expenses has averaged $541250.0 across 5 years, with a median of $274500.0 in 2023.
  • Biggest five-year swings in Accumulated Expenses: tumbled 69.08% in 2024 and later soared 781.98% in 2025.
  • Year by year, Accumulated Expenses stood at $212000.0 in 2021, then fell by 8.96% to $193000.0 in 2022, then surged by 202.07% to $583000.0 in 2023, then soared by 145.11% to $1.4 million in 2024, then dropped by 15.54% to $1.2 million in 2025.
  • Business Quant data shows Accumulated Expenses for SER at $1.2 million in Q4 2025, $1.1 million in Q3 2025, and $1.3 million in Q2 2025.